Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

• Status: Terminated
• Trial end date: 2019-04-10
• Target enrollment: 0
• Participant gender: All

Summary

Multicenter, multinational, randomized, 3-arm, double-blind, phase II clinical study with 2400mg mesalamine, 1200mg mesalamine or placebo for prevention of colorectal neoplasia in Lynch Syndrome patients for 2 years.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Christoph Gasche
• Collaborators: Ann-Sofie Backman, MD PhD, Sweden; Prof. Dr. Gabriela Möslein, Germany; Prof. Dr. Hans Vasen, The Netherlands; Prof. Dr. med. Jan Lubinski, Poland; Prof. Dr. med. Yaron Niv, Israel; Univ. Prof. Dr. Judith Karner-Hanusch, Austria
• Treatments: Aminosalicylic Acid; Mesalamine

Criteria

Inclusion Criteria:

• Proven tumor-free (including patients in which the polyps are removed endoscopically) carriers of a germline pathologic mutation on one of the MMR genes including MLH1, MSH2 (including EpCAM) and MSH6

• Male or female subjects with the age > 25 years

• Females who have been post-menopausal more than one (1) year or females of childbearing potential using a highly efficient method of contraception with less than 1% failure rate (i.e. oral hormonal contraceptives, hormone implants, hormone injections, sterilization, hormonal or copper intrauterine device, sterilized/vasectomized partner, or diaphragm in combination with a condom, spermicide or birth control pills) or should agree to abstain from heterosexual activity during treatment period. Females of childbearing potential must have a negative pregnancy test at screening and before randomization.

• Signed written informed consent prior to inclusion in the study

Exclusion Criteria:

• Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)

• Carriers of germline mutations in PMS2

• Patients with history of stage 3 and 4 colorectal cancer (CRC) are excluded

• Presence of metastatic disease

• Regular use of acetylsalicylic acid (ASA or aspirin): daily use of ≥100mg in more than 3 continuous months within the last year

• Regular use of NSAIDs or COX-2 inhibitors: daily use in more than 3 continuous months within the last year

• Hypersensitivity to 5-ASA

• Patients after total or subtotal colectomy

• Colorectal surgery within the previous 6 months

• Unwillingness to participate or who is considered incompetent to give an informed consent

• Pregnant or breastfeeding women

• Participation in another clinical study investigating another IMP within 3 months prior to screening

• Renal insufficiency (GFR <30ml/min/1.73m2)

• Severe liver disease or liver failure (elevation of liver enzymes above 3xULN)

• Current or history of serious psychiatric disorder or alcohol/drug abuse that in the opinion of the investigator may impact the assessment of IMP safety andefficacy or protocol adherence

• Prior history of myocarditis or pericarditis. Other severe acute or chronic medical condition (such as severe chronic lung (COPD, including asthma), kidney or heart diseases) or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or ability to comply with study procedures, IMP administration and, in the judgment of the investigator, would make the subject inappropriate for entry into this study